Search results for "Biochemistry"

showing 10 items of 20172 documents

Allogeneic Stem Cell Transplantation for Acquired Aplastic Anemia: Better Outcome with Bone Marrow as Compared to Peripheral Blood in HLA-Matched Sib…

2009

Abstract Abstract 876 Background: Transplantation of bone marrow (BM) from a HLA-matched sibling donor is an effective treatment for severe aplastic anemia (AA) with long-term survival in excess of 80%. In the recent years there were two trends in allogeneic stem cell transplantation (SCT) for AA: (1) increasing proportion of transplants performed from matched unrelated donors (MUD) and (2) increasing proportion of transplants using peripheral blood progenitor cells (PBSC) as stem cell source instead of BM. A similar switch to PBSC over BM grafts is reported in leukemia transplants. PBSC grafts for leukemia are associated with higher rates of chronic graft-versus-host disease (cGVHD). This …

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentImmunologyHazard ratioImmunosuppressionCell BiologyHematologyHematopoietic stem cell transplantationmedicine.diseaseBiochemistryGastroenterologySurgeryTransplantationLeukemiasurgical procedures operativeGraft-versus-host diseasemedicine.anatomical_structureInternal medicineparasitic diseasesmedicineBone marrowAplastic anemiabusinessBlood
researchProduct

Relevance of the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) On Non-Relapse Related Mortality (NRM) in Patients with Acute…

2009

Abstract Abstract 3352 Poster Board III-240 Allogeneic HSCT is established as a potent curative therapy in adult patients with high risk ALL. However, due to transplant-related morbidity and lethality the gains in relapse prevention do not necessarily translate into survival advantages in the overall patient population. Defining the role of allogeneic HSCT in ALL patients in first complete remission (CR1) according to leukemia related risk factors, to transplant related risk factors (e.g. HLA matching, conditioning therapy and immunosuppressive treatment), and to comorbidity related risks, remains a major task for upcoming clinical trials. Several retrospective studies suggest that the HCT-…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentImmunologyRetrospective cohort studyCell BiologyHematologyHematopoietic stem cell transplantationTotal body irradiationmedicine.diseaseBiochemistryComorbidityFludarabineSurgeryTransplantationhemic and lymphatic diseasesInternal medicinemedicineCumulative incidenceProspective cohort studybusinessmedicine.drugBlood
researchProduct

AB0467 EFFECTIVENESS OF GOLIMUMAB AFTER TNF-INHIBITOR FAILURE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, OR AXIAL SPONDYLOART…

2021

Background:Golimumab showed trial efficacy in subjects with active rheumatoid arthritis (RA) previously treated with TNF-inhibitors (TNFi); no trial data are available for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).Objectives:To assess the effectiveness of golimumab after TNFi failure in patients with RA, PsA, or axSpA in a real-world setting.Methods:GO-BEYOND-Italy is an ongoing, multicenter, prospective, observational study of RA, PsA, or axSpA patients starting golimumab after TNFi failure. Patients were enrolled between July 2017 and December 2019, and followed for 1 year, with evaluations at 3, 6, and 12 months. This interim analysis estimates the effectiveness after…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentImmunologymedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyInfliximabGolimumabTNF inhibitorEtanerceptPsoriatic arthritisRheumatologyRheumatoid arthritisInternal medicinemedicineAdalimumabImmunology and AllergyAxial spondyloarthritisbusinessmedicine.drugAnnals of the Rheumatic Diseases
researchProduct

Early Mortality in Patients with Multiple Myeloma Treated with Novel Agents - Analysis from Polish Myeloma Study Group

2020

Background Although the introduction of novel agents improved the survival outcomes in patients with multiple myeloma (MM), some patients died within one year (early mortality, EM) following diagnosis. In this study, we evaluated the EM rate, and investigated the risk factors associated with EM in MM patients. Aims In this study we investigated risk factors associated with EM in MM patients initially treated with novel-agent containing regimen. Methods We conducted a multicenter (15 Polish sites) retrospective study a cohort of symptomatic MM pts diagnosed between October 2006 and November 2019 and living < 365 days (d) after diagnosis. All pts were dead at the time of the analysis. …

medicine.medical_specialtybusiness.operationbusiness.industryImmunologyRetrospective cohort studyCell BiologyHematologymedicine.diseaseOctapharmaBiochemistryThalidomideRegimenNovel agentsInternal medicineCohortMedicineIn patientbusinessMultiple myelomamedicine.drugBlood
researchProduct

Impact of Cumulative Dose of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective …

2018

Abstract Background: Triplet-based lenalidomide plus dexamethasone (Rd) combinations have become the new standard of care for early relapse and refractory multiple myeloma (RRMM). Carfilzomib is a novel selective proteasome inhibitor (PI) with high efficacy in RRMM. The ASPIRE phase 3 trial showed the superiority of carfilzomib-based triplet (KRd compared to Rd), leading to approval of K for RRMM. However, little is known about safety and efficacy of KRd outside a clinical trial context. Experimental design and aims: In 11 Sicilian Centers belonging to the Sicilian Myeloma Network, from November 2016, when KRd regimen was approved in Italy, to June 2018, 103 consecutive RRMM patients (previ…

medicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiescomplete remissionImmunologylenalidomideadverse eventContext (language use)dexamethasoneBiochemistrychemistry.chemical_compoundMedian follow-upInternal medicinemedicinecarfilzomib dexamethasone lenalidomide multiple myeloma toxic effect adverse event bortezomib complete remission erythropoietin febrile neutropeniaMultiple myelomaLenalidomidetoxic effectcarfilzomibbusiness.industryCumulative dosebortezomibCell BiologyHematologymedicine.diseaseCarfilzomibmultiple myelomaRegimenfebrile neutropeniachemistryerythropoietinbusinessFebrile neutropeniamedicine.drug
researchProduct

Management of Venous Thromboembolism (VTE) in Patients with Acute Leukemia: Results from a Multicenter Study

2014

Abstract Background In the last decades, evaluation of thrombotic complications secondary to acute leukemia (AL) has been poorly investigated. Only scant data are available on management and prevention of thrombosis in this setting. We performed a multicenter retrospective study with the aim to evaluate the management of venous thromboembolism (VTE) in patients with AL and to report the most commonly adopted regimens of treatment. Materials and methods Available clinical records of out and in-patients diagnosed with AL from January 2008 to June 2013 in 7 Reference Regional Hospitals were analyzed. Cases of VTE, including thrombosis in atypical sites [Retinal occlusion (RO) and Cerebral Sinu…

medicine.medical_specialtyeducation.field_of_studyAcute leukemiabusiness.industrymedicine.drug_classDeep veinImmunologyPopulationLow molecular weight heparinRetrospective cohort studyCell BiologyHematologyFondaparinuxmedicine.diseaseBiochemistrySurgeryPulmonary embolismmedicine.anatomical_structureInternal medicinemedicineMedical historybusinesseducationmedicine.drugBlood
researchProduct

Incidence and Management Of Venous Thrombosis In Acute Leukemia: A Multicenter Study

2013

Abstract Background Venous thrombosis (VT) frequently complicates the clinical course of cancer. Reported incidence of VT in many hematological neoplasms is up to 10%, a value comparable to that of solid tumors. Available data on the incidence and management of VT in Acute Leukemia (AL) are scanty and quite discordant. We have performed a multicenter retrospective study with the primary objective to evaluate the incidence of venous thrombotic complications in a population of patients with AL. Secondary objective was to evaluate the management of these complications in patients with AL. Materials and Methods Available clinical records of out and in-patients diagnosed with AL from January 200…

medicine.medical_specialtyeducation.field_of_studyAcute leukemiamedicine.drug_classbusiness.industryImmunologyAnticoagulantPopulationLow molecular weight heparinCell BiologyHematologymedicine.diseaseBiochemistryGastroenterologyThrombosisSurgeryPulmonary embolismVenous thrombosisInternal medicinemedicineFactor V LeidenbusinesseducationVenous Thromboembolism Acute Leukemia A Multicenter Study
researchProduct

Repeated Echocardiographic Left Ventricular Ejection Fraction Measurements: A Strong and Accessible Tool for Detecting At High Risk of Heart Failure …

2011

Abstract Abstract 3197 Background: The prognosis for thalassemia major (TM) has dramatically improved in the last two decades. However, many transfusion-dependent patients continue to develop secondary iron overloading, and eventually death, particularly from cardiac disease. The possibility of detecting easily and earliest the patients at risk of cardiac death is so far the main challenge of clinical management of these patients. Therefore, the mean reduction of Left Ventricular Ejection Fraction (LVEF), determined by echocardiography, was evaluated over the time. Methods: Among the 413 observed patients only 188 had complete records for LVEF measurements during, at least, five considered …

medicine.medical_specialtyeducation.field_of_studyEjection fractionmedicine.diagnostic_testbusiness.industryImmunologyPopulationMagnetic resonance imagingCell BiologyHematologymedicine.diseaseLogistic regressionBiochemistryGeeSurgeryInternal medicineHeart failureLinear regressionCardiologyMedicinebusinesseducationGeneralized estimating equation
researchProduct

Bortezomib Retreatment in Relapsed Multiple Myeloma (MM): Results from a Binational, Multicenter Retrospective Survey

2008

Abstract In myeloma therapy retreatment after successful therapy is frequently considered. Here we present pooled data from a German and Swiss multicenter, retrospective survey (26866138MMY4014). The survey started in Germany and was later extended to Switzerland. German data have already been published before. Here we report on the entire cohort of patients for the first time. For inclusion into this analysis, patients with MM had to have had preceding bortezomib treatment, resulting in at least partial remission and a second therapy with Bortezomib on relapse. The intention of this trial was to provide further evidence of the value of a retreatment with bortezomib, description of predispo…

medicine.medical_specialtyeducation.field_of_studyIntention-to-treat analysisBortezomibbusiness.industryImmunologyPopulationCell BiologyHematologymedicine.diseaseBiochemistrySurgeryTransplantationConcomitantInternal medicinemedicineAdverse effecteducationbusinessMultiple myelomaDexamethasonemedicine.drugBlood
researchProduct

Polymorphisms of the UCP2 gene are associated with body fat distribution and risk of abdominal obesity in Spanish population

2011

Eur J Clin Invest 2011 Abstract Background  Increased accumulation of fat results from an imbalance between energy expenditure and intake, being modulated by different environmental and genetic factors. Uncoupling proteins (UCPs) are mitochondrial carrier proteins able to spend energy generating heat. Therefore, variations in these genes are good candidates as potential modulators of body fat accumulation. Our aim was to investigate the possible association of genetic variations of the gene codifying the UCP2 protein with obesity and fat distribution. Design  We performed a cross-sectional study in 2367 individuals from two population-based studies from different regions of Spain. The Horte…

medicine.medical_specialtyeducation.field_of_studyWaistClinical BiochemistryPopulationGeneral MedicineBiologymedicine.diseaseBiochemistryObesityEndocrinologyInternal medicineGenetic variationGenotypemedicinemedicine.symptomeducationGeneAbdominal obesityBody fat distributionEuropean Journal of Clinical Investigation
researchProduct